Novel and Cost-Effective Manufacturing Process Development of Daprodustat
- 11 March 2025
- journal article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (3) , 953-963
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Olaparib Process Development Employing Quality by Design (QbD) PrinciplesACS Omega, 2024
- Efficient Process Development of Abiraterone Acetate by Employing Design of ExperimentsACS Omega, 2024
- Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal AssociationNephrology Dialysis Transplantation, 2024
- Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemiaClinical Kidney Journal, 2024
- Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal AnemiaKidney Diseases, 2022
- Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney diseaseKidney International Supplements, 2021
- Daprodustat: First ApprovalDrugs, 2020
- Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for AnemiaThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis SubjectsAmerican Journal of Nephrology, 2016
- Design of Experiments (DoE) and Process Optimization. A Review of Recent PublicationsOrganic Process Research & Development, 2014